
- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objective:To study the Oriental Medicine-based strategies or therapeutics for chronic HBV infection. Methods:A chronic HBV carrier was treated with only oriental therapies. Then, serum biochemical parameters were serially chased, and change of HBV-DNA level was evaluated. Result:The biochemical indicators (AST, ALT, gamma-GTP, bilirubin) fluctuated during the treatment period. After one episode of drastic elevation of serum aminotransferase, HBV-DNA disappeared from the blood along with normalization of biochemical parameters within two years of beginning treatment. Conclusion:Oriental Medicine-based therapeutics could be an alternative strategy against chronic infection of HBV.
Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-45.
de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. J Hepatol. 2003;39:S3-25.
Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34:S1-3.
Han KH, Kim JK. Liver cancer in Korea. Hepatol Res. 2007;37:S106-9.
Shao ZJ, Xu DZ, Xu JQ, Li JH, Yan YP, Men K, et al. Maternal hepatitis B virus DNA positivity and sexual intercourse are associated with HBV intrauterine transmissionin China: a prospective case-control study. J Gastroenterol Hepatol. 2007;22:165-70.
KNSO, Koean motality and causes of death in 2003. 2004.
Leemans WF, Janssen HL, de Man RA. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol. 2007;13:2554-67.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
Perrillo RP, Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009-22.
Missale G. Comparative pathogenesis of HBV and HCV. Virus Res. 2002;82:19-23.
Rapicetta MC, Ferrari M Levrero. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol. 2002;67:454-7.
Michel ML. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine. 2001;19:2395-9.
Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992-1000.
Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis. 2001;5:109-22.
Velazquez RF. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520-7.
Son CG. A Clinical Report of Adult Acute Viral Hepatitis Type A Treated with Herbal Prescription. J Korean Oriental Med 2007;28:124-30.
Cho JH, Seo SH, Yoo HS, Lee YW, Choi WJ, Son CG, et al. A Clinical Report about 57 Patients with Chronic Liver Disease. J. Korean Oriental Medicine. 2000;21:111-21.
Shin JW, Son JY, Oh SM, Han SH, Wang JH, Cho JH, et al. An herbal formula, CGX, exerts hepatotherapeutic effects on dimethylnitrosamineinduced chronic liver injury model in rats. World J Gastroenterol. 2006;12:6142-8.
Chang JS, Liu HW, Wang KC, Chen MC, Chiang LC, Hua YC, et al. Ethanol extract of Polygonum cuspidatum inhibits hepatitis B virus in a stable HBV-producing cell line. Antiviral Res. 2005;66:29-34.
Lee JE , Kim CW, Jung YJ, Rhew KY, Kim YC, Lee JH, et al. Two Cases of Injinchunggan-tang treated patients with chronic hepatitis B relapsed after lamivudine therapy. J. of Korean Internal Medicine. 2005;Spring(1):230-9.
Kim SH, Seo SH, Hong SH. The study of the effects of Gagamchunggan-tang on chronic hepatitis. J. of Korean Internal Medicine. 2003; Autumn(1):185-90.